---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-078049"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2023-09-20T23:59:59+00:00"
generated_at: "2026-06-10T12:00:58.757363+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Relmada reports Phase 3 open-label data for REL-1017 in MDD: rapid, sustained symptom improvement

## Summary
- In 204 de novo patients, mean MADRS total score improved 11.3 points at Day 7 and 22.5 points at Month 12.
- Clinical response (≥50% MADRS improvement) achieved by 26.6% at Day 7 and 77.2% at Month 12.
- Remission (MADRS ≤10) rates were 12.1% at Day 7 and 54.4% at Month 12.
- Safety: ~3% discontinuation due to AEs; no new safety signals; common AEs were headache (4.4%), nausea (4.0%), dizziness (2.4%).
- Functional impairment (SDS) improved ~50% by Month 6 in de novo patients.

## SEC filing metadata
- accession: 0001213900-23-078049
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2023-09-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390023078049/0001213900-23-078049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390023078049/ea185487-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-078049
- JSON: https://secwatch.observer/filing/0001213900-23-078049.json
- Plain text: https://secwatch.observer/filing/0001213900-23-078049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.